Home LiteratureArticle Details
PMID: 19568407 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.

Neoplasia (New York, N.Y.) ·Vol. 11 ·No. 7 ·2009-07-00 ·Pages 615-28

Srikrishna G, Freeze HH

Abstract

Inflammatory mediators play important roles in the development and progression of cancer. Cellular stress, damage, inflammation, and necrotic cell death cause release of endogenous damage-associated molecular pattern (DAMP) molecules or alarmins, which alert the host of danger by triggering immune responses and activating repair mechanisms through their interaction with pattern recognition receptors. Recent studies show that abnormal persistence of these molecules in chronic inflammation and in tumor microenvironments underlies carcinogenesis and tumor progression, indicating that DAMP molecules and their receptors could provide novel targets for therapy. This review focuses on the role of DAMP molecules high-mobility group box 1 and S100 proteins in inflammation, tumor growth, and early metastatic events.

MeSH Terms
Animals HMGB1 Protein/physiology Humans Inflammation/physiopathology Inflammation Mediators/physiology Neoplasms/physiopathology
Chemicals
HMGB1 Protein Inflammation Mediators
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Srikrishna Geetha
Tumor Microenvironment Program, Cancer Center, The Burnham Institute for Medical Research, La Jolla, CA 92037, USA. gsrikrishna@burnham.org
Freeze Hudson H
References (231)
231 references, click to expand
  1. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis.
    Carcinogenesis. 2008 Oct;29(10):2035-43 PMID: 18689872
  2. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles.
    Int J Biochem Cell Biol. 2001 Jul;33(7):637-68 PMID: 11390274
  3. Expression of receptor for advanced glycation end products (RAGE) is related to prognosis in patients with esophageal squamous cell carcinoma.
    Ann Surg Oncol. 2009 Feb;16(2):440-6 PMID: 19023628
  4. HMGB1: endogenous danger signaling.
    Mol Med. 2008 Jul-Aug;14(7-8):476-84 PMID: 18431461
  5. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE.
    J Exp Med. 2008 Dec 22;205(13):3007-18 PMID: 19064698
  6. Novel carboxylated N-glycans contain oligosaccharide-linked glutamic acid.
    Biochem Biophys Res Commun. 2005 Jul 15;332(4):1020-7 PMID: 15922305
  7. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways.
    J Biol Chem. 1999 Jul 9;274(28):19919-24 PMID: 10391939
  8. Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin. Enhancement of t-PA-catalyzed plasminogen activation by amphoterin.
    J Biol Chem. 1991 Sep 5;266(25):16730-5 PMID: 1909331
  9. Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays.
    Biochem Biophys Res Commun. 2003 Jul 25;307(2):375-81 PMID: 12859967
  10. A null mutation in the inflammation-associated S100 protein S100A8 causes early resorption of the mouse embryo.
    J Immunol. 1999 Aug 15;163(4):2209-16 PMID: 10438963
  11. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors.
    Semin Immunol. 2007 Feb;19(1):3-10 PMID: 17275324
  12. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer.
    Cell. 2004 Aug 6;118(3):285-96 PMID: 15294155
  13. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA.
    Blood. 2007 Sep 15;110(6):1970-81 PMID: 17548579
  14. Systemic inflammation and remote organ injury following trauma require HMGB1.
    Am J Physiol Regul Integr Comp Physiol. 2007 Oct;293(4):R1538-44 PMID: 17652366
  15. Pathogen recognition with Toll-like receptors.
    Curr Opin Immunol. 2005 Aug;17(4):338-44 PMID: 15950447
  16. Signaling to NF-kappaB by Toll-like receptors.
    Trends Mol Med. 2007 Nov;13(11):460-9 PMID: 18029230
  17. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization.
    J Immunol. 2004 Jul 1;173(1):307-13 PMID: 15210788
  18. Identification, classification, and expression of RAGE gene splice variants.
    FASEB J. 2008 May;22(5):1572-80 PMID: 18089847
  19. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis.
    Nature. 1987 Nov 5-11;330(6143):80-2 PMID: 3313057
  20. Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products.
    Cardiovasc Diabetol. 2006 Mar 30;5:6 PMID: 16573830
  21. Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15.
    J Immunol. 2008 Jul 15;181(2):1499-506 PMID: 18606705
  22. Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling.
    Cancer Res. 1999 Jul 15;59(14):3299-303 PMID: 10416581
  23. Myeloid cell function in MRP-14 (S100A9) null mice.
    Mol Cell Biol. 2003 Apr;23(7):2564-76 PMID: 12640137
  24. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine.
    Arthritis Rheum. 2003 Apr;48(4):971-81 PMID: 12687539
  25. High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo.
    J Neurochem. 2007 Oct;103(2):590-603 PMID: 17666052
  26. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis.
    Arthritis Rheum. 2002 Oct;46(10):2598-603 PMID: 12384917
  27. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products.
    J Immunol. 2005 Jun 15;174(12):7506-15 PMID: 15944249
  28. Derangement of immune responses by myeloid suppressor cells.
    Cancer Immunol Immunother. 2004 Feb;53(2):64-72 PMID: 14593498
  29. RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth.
    Am J Pathol. 2007 Sep;171(3):947-61 PMID: 17640970
  30. Cancer and complement.
    Nat Biotechnol. 2008 Dec;26(12):1348-9 PMID: 19060872
  31. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature).
    Biochem Biophys Res Commun. 2004 Oct 1;322(4):1111-22 PMID: 15336958
  32. S100 proteins: structure, functions and pathology.
    Front Biosci. 2002 May 01;7:d1356-68 PMID: 11991838
  33. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia.
    Nature. 2003 Feb 6;421(6923):639-43 PMID: 12571598
  34. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules.
    J Leukoc Biol. 2007 Jan;81(1):28-37 PMID: 16943388
  35. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis.
    Cancer Res. 2002 Aug 15;62(16):4805-11 PMID: 12183440
  36. The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells.
    J Biol Chem. 2002 Feb 1;277(5):3658-65 PMID: 11723110
  37. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling.
    Immunity. 2004 Oct;21(4):491-501 PMID: 15485627
  38. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes.
    J Exp Med. 2000 Aug 21;192(4):565-70 PMID: 10952726
  39. Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma.
    Cancer. 2007 Jun 15;109(12):2532-40 PMID: 17497647
  40. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation.
    J Cell Biol. 2004 Feb 2;164(3):441-9 PMID: 14744997
  41. S100B's double life: intracellular regulator and extracellular signal.
    Biochim Biophys Acta. 2009 Jun;1793(6):1008-22 PMID: 19110011
  42. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation.
    J Biol Chem. 2000 Dec 22;275(51):40096-105 PMID: 11007787
  43. The expression of the receptor for glycation endproducts (RAGE) in oral squamous cell carcinomas.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 May;105(5):617-24 PMID: 18206396
  44. Inflammation and necrosis promote tumour growth.
    Nat Rev Immunol. 2004 Aug;4(8):641-8 PMID: 15286730
  45. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells.
    J Immunol. 2008 Oct 1;181(7):4666-75 PMID: 18802069
  46. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells.
    J Cell Biol. 2001 Mar 19;152(6):1197-206 PMID: 11257120
  47. Absence of S100A12 in mouse: implications for RAGE-S100A12 interaction.
    Trends Immunol. 2003 Dec;24(12):622-4 PMID: 14644132
  48. Influence of the mannose receptor in host immune responses.
    Immunobiology. 2009;214(7):554-61 PMID: 19162368
  49. HMG-1 as a late mediator of endotoxin lethality in mice.
    Science. 1999 Jul 9;285(5425):248-51 PMID: 10398600
  50. A cytokine-mediated link between innate immunity, inflammation, and cancer.
    J Clin Invest. 2007 May;117(5):1175-83 PMID: 17476347
  51. Chemoprevention of colorectal cancer.
    Am J Gastroenterol. 2002 Jan;97(1):13-21 PMID: 11808936
  52. Cancer in inflammatory bowel disease.
    World J Gastroenterol. 2008 Jan 21;14(3):378-89 PMID: 18200660
  53. Understanding RAGE, the receptor for advanced glycation end products.
    J Mol Med (Berl). 2005 Nov;83(11):876-86 PMID: 16133426
  54. Role of HMGB1 in apoptosis-mediated sepsis lethality.
    J Exp Med. 2006 Jul 10;203(7):1637-42 PMID: 16818669
  55. Tolerance, danger, and the extended family.
    Annu Rev Immunol. 1994;12:991-1045 PMID: 8011301
  56. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin).
    J Leukoc Biol. 2007 Jan;81(1):49-58 PMID: 16980512
  57. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer.
    Clin Cancer Res. 2005 Jul 15;11(14):5146-52 PMID: 16033829
  58. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1).
    Angiogenesis. 2008;11(1):91-9 PMID: 18264787
  59. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides.
    Cell. 1999 Jun 25;97(7):889-901 PMID: 10399917
  60. Tumor escape mechanism governed by myeloid-derived suppressor cells.
    Cancer Res. 2008 Apr 15;68(8):2561-3 PMID: 18413722
  61. N -Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth.
    J Neurochem. 2002 Mar;80(6):998-1008 PMID: 11953450
  62. Myeloid-derived suppressor cell role in tumor-related inflammation.
    Cancer Lett. 2008 Aug 28;267(2):216-25 PMID: 18433992
  63. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system.
    Nat Med. 2003 Mar;9(3):287-93 PMID: 12598893
  64. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein.
    J Biol Chem. 2004 Feb 27;279(9):7370-7 PMID: 14660645
  65. Unusual anionic N-linked oligosaccharides from bovine lung.
    J Biol Chem. 1995 Nov 17;270(46):27634-45 PMID: 7499228
  66. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule.
    Am J Pathol. 2005 Apr;166(4):1259-63 PMID: 15793304
  67. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein.
    J Exp Med. 2008 Sep 29;205(10):2235-49 PMID: 18809714
  68. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing.
    N Engl J Med. 1986 Dec 25;315(26):1650-9 PMID: 3537791
  69. Activation of gene expression in human neutrophils by high mobility group box 1 protein.
    Am J Physiol Cell Physiol. 2003 Apr;284(4):C870-9 PMID: 12620891
  70. Myeloid-derived suppressor cells.
    Adv Exp Med Biol. 2007;601:213-23 PMID: 17713008
  71. High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis.
    Arthritis Rheum. 2003 Jun;48(6):1693-700 PMID: 12794838
  72. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.
    Nature. 2000 May 18;405(6784):354-60 PMID: 10830965
  73. Multivalent protein-carbohydrate interactions. A new paradigm for supermolecular assembly and signal transduction.
    Biochemistry. 2001 Mar 13;40(10):3009-15 PMID: 11258914
  74. Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma.
    Carcinogenesis. 2005 Feb;26(2):293-301 PMID: 15539404
  75. Toll-like receptors, wound healing, and carcinogenesis.
    J Mol Med (Berl). 2009 Feb;87(2):125-38 PMID: 19089397
  76. Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation.
    J Biol Chem. 1993 Sep 15;268(26):19726-38 PMID: 8366113
  77. Inflammation, atrophy, and gastric cancer.
    J Clin Invest. 2007 Jan;117(1):60-9 PMID: 17200707
  78. Relationship between schistosomiasis and bladder cancer.
    Clin Microbiol Rev. 1999 Jan;12(1):97-111 PMID: 9880476
  79. Toll-like receptors and cancer.
    Nat Rev Cancer. 2009 Jan;9(1):57-63 PMID: 19052556
  80. Viral sensors: diversity in pathogen recognition.
    Immunol Rev. 2009 Jan;227(1):87-94 PMID: 19120478
  81. Molecular characteristics of immunogenic cancer cell death.
    Cell Death Differ. 2008 Jan;15(1):3-12 PMID: 18007663
  82. The inflammatory response to cell death.
    Annu Rev Pathol. 2008;3:99-126 PMID: 18039143
  83. A novel anionic modification of N-glycans on mammalian endothelial cells is recognized by activated neutrophils and modulates acute inflammatory responses.
    J Immunol. 2001 Jan 1;166(1):624-32 PMID: 11123346
  84. High mobility group 1 B-box mediates activation of human endothelium.
    J Intern Med. 2003 Oct;254(4):375-85 PMID: 12974876
  85. The impact of endogenous triggers on trauma-associated inflammation.
    Curr Opin Crit Care. 2006 Dec;12(6):595-601 PMID: 17077693
  86. Cytokines: from gut inflammation to colorectal cancer.
    Curr Drug Targets. 2008 May;9(5):375-80 PMID: 18473765
  87. Multiple effects of high mobility group box protein 1 in skeletal muscle regeneration.
    Arterioscler Thromb Vasc Biol. 2007 Nov;27(11):2377-83 PMID: 17872450
  88. Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo.
    Shock. 2009 Mar;31(3):280-4 PMID: 19218854
  89. Cancer genes and the pathways they control.
    Nat Med. 2004 Aug;10(8):789-99 PMID: 15286780
  90. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses.
    J Clin Invest. 2001 Oct;108(7):949-55 PMID: 11581294
  91. S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells.
    Exp Cell Res. 2006 Jan 15;312(2):184-97 PMID: 16297907
  92. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains.
    J Biol Chem. 2007 Oct 26;282(43):31317-31 PMID: 17726019
  93. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells.
    Circ Res. 2007 Feb 2;100(2):204-12 PMID: 17218606
  94. Masquerader: high mobility group box-1 and cancer.
    Clin Cancer Res. 2007 May 15;13(10):2836-48 PMID: 17504981
  95. Hemorrhage-induced acute lung injury is TLR-4 dependent.
    Am J Physiol Regul Integr Comp Physiol. 2004 Sep;287(3):R592-9 PMID: 15072965
  96. Contradictory functions of NF-kappaB in liver physiology and cancer.
    Cancer Lett. 2008 Aug 28;267(2):182-8 PMID: 18479806
  97. RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease.
    Curr Mol Med. 2007 Dec;7(8):735-42 PMID: 18331231
  98. Origin and physiological roles of inflammation.
    Nature. 2008 Jul 24;454(7203):428-35 PMID: 18650913
  99. Heparin-binding proteins HB-GAM (pleiotrophin) and amphoterin in the regulation of cell motility.
    Matrix Biol. 2000 Sep;19(5):377-87 PMID: 10980414
  100. Neurite growth-promoting protein (amphoterin, p30) binds syndecan.
    Exp Cell Res. 1992 Jun;200(2):444-51 PMID: 1369684
  101. The tumor microenvironment and its role in promoting tumor growth.
    Oncogene. 2008 Oct 6;27(45):5904-12 PMID: 18836471
  102. Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjögren's syndrome.
    Arthritis Rheum. 2006 Jul;54(7):2289-94 PMID: 16802368
  103. HMG1 and 2, and related 'architectural' DNA-binding proteins.
    Trends Biochem Sci. 2001 Mar;26(3):167-74 PMID: 11246022
  104. NF-kappaB: linking inflammation and immunity to cancer development and progression.
    Nat Rev Immunol. 2005 Oct;5(10):749-59 PMID: 16175180
  105. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer.
    Trends Mol Med. 2008 Mar;14(3):109-19 PMID: 18261959
  106. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis.
    Cell. 2006 Jan 27;124(2):263-6 PMID: 16439202
  107. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products.
    Circ Res. 2008 May 23;102(10):1239-46 PMID: 18403730
  108. High-mobility group box 1 protein in human and murine skin: involvement in wound healing.
    J Invest Dermatol. 2008 Jun;128(6):1545-53 PMID: 18239618
  109. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB.
    Diabetes. 2001 Dec;50(12):2792-808 PMID: 11723063
  110. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis.
    Cell. 2005 Jul 1;121(7):977-90 PMID: 15989949
  111. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.
    Nat Rev Immunol. 2007 Jan;7(1):41-51 PMID: 17186030
  112. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro.
    Mol Cell Biol. 2003 Feb;23(3):1034-43 PMID: 12529407
  113. Tumor-host interactions: the role of inflammation.
    Histochem Cell Biol. 2008 Dec;130(6):1079-90 PMID: 18953558
  114. Cancer related inflammation: the macrophage connection.
    Cancer Lett. 2008 Aug 28;267(2):204-15 PMID: 18448242
  115. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells.
    Blood. 2003 Apr 1;101(7):2652-60 PMID: 12456506
  116. Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling.
    J Immunol. 2007 May 15;178(10):6573-80 PMID: 17475888
  117. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal.
    Nat Rev Immunol. 2005 Apr;5(4):331-42 PMID: 15803152
  118. Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion.
    J Immunol. 2006 Dec 1;177(11):7889-97 PMID: 17114460
  119. Pathways connecting inflammation and cancer.
    Curr Opin Genet Dev. 2008 Feb;18(1):3-10 PMID: 18325755
  120. Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock.
    Mol Med. 2006 Apr-Jun;12(4-6):105-14 PMID: 16953558
  121. Innate immunity--cross-talk with adaptive immunity through pattern recognition receptors and cytokines.
    Curr Opin Immunol. 2007 Feb;19(1):1-3 PMID: 17157490
  122. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins.
    J Biol Chem. 1992 Jul 25;267(21):14998-5004 PMID: 1378843
  123. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.
    J Natl Cancer Inst. 2002 Feb 20;94(4):252-66 PMID: 11854387
  124. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation.
    Circ Res. 2005 Oct 14;97(8):e73-83 PMID: 16166556
  125. AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice.
    Am J Physiol Heart Circ Physiol. 2008 Aug;295(2):H491-8 PMID: 18539754
  126. Active caspase-1 is a regulator of unconventional protein secretion.
    Cell. 2008 Mar 7;132(5):818-31 PMID: 18329368
  127. Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding.
    Mol Cell Biol. 2004 Jun;24(11):4880-94 PMID: 15143181
  128. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype.
    Mol Cell Biol. 2003 Apr;23(8):2991-8 PMID: 12665595
  129. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence.
    J Natl Cancer Inst. 2007 Apr 18;99(8):608-15 PMID: 17440162
  130. The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis.
    Arthritis Res Ther. 2006;8(3):R69 PMID: 16613612
  131. Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages.
    Am J Pathol. 2005 Mar;166(3):751-60 PMID: 15743787
  132. HMGB1 as a cytokine and therapeutic target.
    J Endotoxin Res. 2002;8(6):469-72 PMID: 12697092
  133. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein.
    FASEB J. 2006 Dec;20(14):2565-6 PMID: 17060403
  134. A review of the S100 proteins in cancer.
    Eur J Surg Oncol. 2008 Apr;34(4):357-64 PMID: 17566693
  135. Neo-ligands for innate immune receptors and the etiology of sterile inflammatory disease.
    Immunol Rev. 2007 Dec;220:113-28 PMID: 17979843
  136. Structural and functional insights into RAGE activation by multimeric S100B.
    EMBO J. 2007 Aug 22;26(16):3868-78 PMID: 17660747
  137. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response.
    J Mol Med (Berl). 2009 Mar;87(3):235-47 PMID: 19189073
  138. Binding of S100 proteins to RAGE: an update.
    Biochim Biophys Acta. 2009 Jun;1793(6):993-1007 PMID: 19121341
  139. Nod1/RICK and TLR signaling regulate chemokine and antimicrobial innate immune responses in mesothelial cells.
    J Immunol. 2007 Jul 1;179(1):514-21 PMID: 17579072
  140. RAGE and RAGE ligands in cancer.
    Curr Mol Med. 2007 Dec;7(8):777-89 PMID: 18331236
  141. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia.
    Shock. 2006 Jun;25(6):571-4 PMID: 16721263
  142. High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists.
    J Immunol. 2006 Dec 15;177(12):8701-7 PMID: 17142771
  143. TLR4 activation mediates kidney ischemia/reperfusion injury.
    J Clin Invest. 2007 Oct;117(10):2847-59 PMID: 17853945
  144. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.
    J Immunother. 2007 Sep;30(6):596-606 PMID: 17667523
  145. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock.
    Nat Med. 2007 Sep;13(9):1042-9 PMID: 17767165
  146. HLA-DR+ immature cells exhibit reduced antigen-presenting cell function but respond to CD40 stimulation.
    Neoplasia. 2005 Dec;7(12):1123-32 PMID: 16354595
  147. HMGB1 contributes to the development of acute lung injury after hemorrhage.
    Am J Physiol Lung Cell Mol Physiol. 2005 May;288(5):L958-65 PMID: 15640285
  148. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis.
    Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):652-6 PMID: 18178624
  149. Cancer-related inflammation.
    Nature. 2008 Jul 24;454(7203):436-44 PMID: 18650914
  150. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
    Nat Med. 2007 Sep;13(9):1050-9 PMID: 17704786
  151. Tumors sound the alarmin(s).
    Cancer Res. 2008 Aug 15;68(16):6482-5 PMID: 18701469
  152. Proinflammatory properties of the human S100 protein S100A12.
    J Leukoc Biol. 2001 Jun;69(6):986-94 PMID: 11404386
  153. Immunogenic cancer cell death: a key-lock paradigm.
    Curr Opin Immunol. 2008 Oct;20(5):504-11 PMID: 18573340
  154. Inflammation and cancer: back to Virchow?
    Lancet. 2001 Feb 17;357(9255):539-45 PMID: 11229684
  155. HMGB1 develops enhanced proinflammatory activity by binding to cytokines.
    J Immunol. 2008 Feb 15;180(4):2531-7 PMID: 18250463
  156. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE.
    Nat Immunol. 2007 May;8(5):487-96 PMID: 17417641
  157. S100B/RAGE-dependent activation of microglia via NF-kappaB and AP-1 Co-regulation of COX-2 expression by S100B, IL-1beta and TNF-alpha.
    Neurobiol Aging. 2010 Apr;31(4):665-77 PMID: 18599158
  158. Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer.
    Biochem Biophys Res Commun. 2007 Aug 24;360(2):394-400 PMID: 17599806
  159. Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine.
    J Immunol. 2006 Jan 1;176(1):12-5 PMID: 16365390
  160. Inflammation and cancer.
    Nature. 2002 Dec 19-26;420(6917):860-7 PMID: 12490959
  161. V domain of RAGE interacts with AGEs on prostate carcinoma cells.
    Prostate. 2008 May 15;68(7):748-58 PMID: 18302220
  162. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway.
    EMBO Rep. 2002 Oct;3(10):995-1001 PMID: 12231511
  163. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules.
    Trends Immunol. 2003 Apr;24(4):155-8 PMID: 12697438
  164. Oxyradicals and DNA damage.
    Carcinogenesis. 2000 Mar;21(3):361-70 PMID: 10688856
  165. High mobility group box 1 protein interacts with multiple Toll-like receptors.
    Am J Physiol Cell Physiol. 2006 Mar;290(3):C917-24 PMID: 16267105
  166. HMGB1: a two-headed signal regulating tumor progression and immunity.
    Curr Opin Immunol. 2008 Oct;20(5):518-23 PMID: 18599281
  167. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression.
    Cancer Immunol Immunother. 2005 Nov;54(11):1137-42 PMID: 15877228
  168. The structure of S100A12 in a hexameric form and its proposed role in receptor signalling.
    Acta Crystallogr D Biol Crystallogr. 2002 Mar;58(Pt 3):407-13 PMID: 11856825
  169. Cloning and expression of two human genes encoding calcium-binding proteins that are regulated during myeloid differentiation.
    Mol Cell Biol. 1988 Jun;8(6):2402-10 PMID: 3405210
  170. Cytokines in cancer immunity and immunotherapy.
    Immunol Rev. 2004 Dec;202:275-93 PMID: 15546400
  171. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88.
    Science. 2007 Jul 6;317(5834):124-7 PMID: 17615359
  172. Preparing the "soil": the premetastatic niche.
    Cancer Res. 2006 Dec 1;66(23):11089-93 PMID: 17145848
  173. RAGE signaling sustains inflammation and promotes tumor development.
    J Exp Med. 2008 Feb 18;205(2):275-85 PMID: 18208974
  174. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas.
    Virchows Arch. 2005 Apr;446(4):411-5 PMID: 15789216
  175. Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products.
    J Immunol. 2005 Dec 15;175(12):8296-302 PMID: 16339570
  176. Two proteins modulating transendothelial migration of leukocytes recognize novel carboxylated glycans on endothelial cells.
    J Immunol. 2001 Apr 1;166(7):4678-88 PMID: 11254728
  177. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system.
    J Biol Chem. 1995 Oct 27;270(43):25752-61 PMID: 7592757
  178. RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways.
    Dis Colon Rectum. 2007 Aug;50(8):1230-40 PMID: 17587138
  179. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response.
    Curr Mol Med. 2007 Dec;7(8):743-51 PMID: 18331232
  180. Toll-like receptor signalling.
    Nat Rev Immunol. 2004 Jul;4(7):499-511 PMID: 15229469
  181. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism.
    Cancer Res. 2000 Jan 1;60(1):184-90 PMID: 10646872
  182. S100A8 and S100A9 in inflammation and cancer.
    Biochem Pharmacol. 2006 Nov 30;72(11):1622-31 PMID: 16846592
  183. Activation of RAGE induces elevated O2- generation by mononuclear phagocytes in diabetes.
    J Leukoc Biol. 2007 Feb;81(2):520-7 PMID: 17095613
  184. Signaling pathways downstream of pattern-recognition receptors and their cross talk.
    Annu Rev Biochem. 2007;76:447-80 PMID: 17328678
  185. How dying cells alert the immune system to danger.
    Nat Rev Immunol. 2008 Apr;8(4):279-89 PMID: 18340345
  186. S100A8 and S100A9 in inflammatory diseases.
    Lancet. 2001 Mar 31;357(9261):1041 PMID: 11293617
  187. New functions for the matrix metalloproteinases in cancer progression.
    Nat Rev Cancer. 2002 Mar;2(3):161-74 PMID: 11990853
  188. Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells.
    J Biol Chem. 2006 May 12;281(19):13685-13693 PMID: 16551628
  189. Inflammatory cell infiltration of tumors: Jekyll or Hyde.
    Cancer Metastasis Rev. 2007 Dec;26(3-4):373-400 PMID: 17717638
  190. Inflammation and cancer: an epidemiological perspective.
    Novartis Found Symp. 2004;256:6-21; discussion 22-8, 49-52, 266-9 PMID: 15027481
  191. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus.
    Arthritis Rheum. 2005 Nov;52(11):3639-45 PMID: 16255056
  192. Cytokine-based transformation of immune surveillance into tumor-promoting inflammation.
    Oncogene. 2008 Oct 6;27(45):5913-9 PMID: 18836472
  193. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors.
    Cancer Res. 2001 Feb 15;61(4):1569-77 PMID: 11245467
  194. Carboxylated glycans mediate colitis through activation of NF-kappa B.
    J Immunol. 2005 Oct 15;175(8):5412-22 PMID: 16210648
  195. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2.
    Shock. 2006 Aug;26(2):174-9 PMID: 16878026
  196. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice.
    Nat Genet. 1999 Jul;22(3):276-80 PMID: 10391216
  197. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation.
    Nature. 2001 Feb 8;409(6821):733-9 PMID: 11217864
  198. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.
    Nature. 2002 Jul 11;418(6894):191-5 PMID: 12110890
  199. Dealing with death: HMGB1 as a novel target for cancer therapy.
    Curr Opin Investig Drugs. 2003 Dec;4(12):1405-9 PMID: 14763124
  200. HMGB1: a signal of necrosis.
    Autoimmunity. 2007 Jun;40(4):285-9 PMID: 17516211
  201. S100P promotes pancreatic cancer growth, survival, and invasion.
    Clin Cancer Res. 2005 Aug 1;11(15):5356-64 PMID: 16061848
  202. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis.
    Nat Cell Biol. 2006 Dec;8(12):1369-75 PMID: 17128264
  203. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity.
    Immunol Rev. 2007 Dec;220:60-81 PMID: 17979840
  204. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase.
    Nat Cell Biol. 2008 Nov;10(11):1349-55 PMID: 18820689
  205. Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2.
    Oncology. 2005;69 Suppl 1:28-32 PMID: 16210874
  206. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages.
    Scand J Immunol. 2005 Jan;61(1):1-9 PMID: 15644117
  207. NF-kappaB functions as a tumour promoter in inflammation-associated cancer.
    Nature. 2004 Sep 23;431(7007):461-6 PMID: 15329734
  208. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression.
    Semin Cancer Biol. 2006 Feb;16(1):53-65 PMID: 16168663
  209. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators.
    Semin Cancer Biol. 2006 Feb;16(1):38-52 PMID: 16139507
  210. Extracellular role of HMGB1 in inflammation and sepsis.
    J Intern Med. 2004 Mar;255(3):320-31 PMID: 14871456
  211. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway.
    J Biol Chem. 1997 Apr 4;272(14):9496-502 PMID: 9083090
  212. DAMPs, PAMPs and alarmins: all we need to know about danger.
    J Leukoc Biol. 2007 Jan;81(1):1-5 PMID: 17032697
  213. NF-kappaB inhibition: a double-edged sword in cancer?
    Eur J Cancer. 2006 Apr;42(6):779-84 PMID: 16530406
  214. Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells.
    Blood. 2005 Apr 1;105(7):2955-62 PMID: 15598812
  215. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion.
    J Exp Med. 2005 Apr 4;201(7):1135-43 PMID: 15795240
  216. RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins.
    Curr Mol Med. 2007 Dec;7(8):711-24 PMID: 18331229
  217. Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches.
    J Biol Chem. 2007 Feb 9;282(6):4218-31 PMID: 17158877
  218. A population of HLA-DR+ immature cells accumulates in the blood dendritic cell compartment of patients with different types of cancer.
    Neoplasia. 2005 Dec;7(12):1112-22 PMID: 16354594
  219. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues.
    Am J Pathol. 1993 Dec;143(6):1699-712 PMID: 8256857
  220. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors.
    Gastroenterology. 2007 Dec;133(6):1869-81 PMID: 18054559
  221. Myeloid-related proteins rapidly modulate macrophage nitric oxide production during innate immune response.
    J Immunol. 2008 Sep 1;181(5):3595-601 PMID: 18714033
  222. The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo.
    J Biol Chem. 2006 Mar 24;281(12):8242-53 PMID: 16407300
  223. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway.
    J Leukoc Biol. 2008 Jun;83(6):1484-92 PMID: 18339893
  224. The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units.
    Biochemistry. 2007 Jun 12;46(23):6957-70 PMID: 17508727
  225. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.
    Science. 2007 Jul 6;317(5834):121-4 PMID: 17615358
  226. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes.
    Surgery. 1999 Aug;126(2):389-92 PMID: 10455911
  227. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion.
    EMBO J. 2003 Oct 15;22(20):5551-60 PMID: 14532127
  228. Pattern recognition receptors and control of adaptive immunity.
    Immunol Rev. 2009 Jan;227(1):221-33 PMID: 19120487
  229. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin.
    J Leukoc Biol. 2007 Jan;81(1):59-66 PMID: 16966386
  230. Pathogen recognition by innate receptors.
    J Infect Chemother. 2008 Apr;14(2):86-92 PMID: 18622669
  231. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer.
    Hum Immunol. 2008 Nov;69(11):811-4 PMID: 18817828
Article Info
Journal
Neoplasia (New York, N.Y.)
Abbr.
Neoplasia
ISSN
1476-5586
DOI
10.1593/neo.09284
Email
gsrikrishna@burnham.org
Published
2009-07-00
Pages
615-28
Language
English
Region
United States
NLM ID
100886622
PMCID
PMC2697348
Subset
IM
Grants
NCI NIH HHS · R01 CA092608 · United States
NCI NIH HHS · R21 CA127780 · United States
NCI NIH HHS · R21-CA127780 · United States
NCI NIH HHS · R01-CA92608 · United States
External Links
PubMed source DOI: 10.1593/neo.09284 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2